Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Short Communication

Delayed response and survival from NovoTTF-100A in recurrent GBM

verfasst von: J. Lee Villano, Leena E. Williams, Karriem S. Watson, Nandini Ignatius, Marquess T. Wilson, Tibor Valyi-Nagy, Edward A. Michals, Herbert H. Engelhard

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.
Literatur
1.
Zurück zum Zitat Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.PubMedCrossRef Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.PubMedCrossRef
2.
Zurück zum Zitat Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, et al. Long-term survival after gene therapy for a recurrent glioblastoma. Neurology. 2002;58:1109–12.PubMedCrossRef Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, et al. Long-term survival after gene therapy for a recurrent glioblastoma. Neurology. 2002;58:1109–12.PubMedCrossRef
3.
Zurück zum Zitat Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys. 2009;75:1162–5.PubMedCrossRef Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys. 2009;75:1162–5.PubMedCrossRef
4.
Zurück zum Zitat Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9.PubMedCrossRef Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9.PubMedCrossRef
5.
Zurück zum Zitat Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir. 2009;151:1349–58.PubMedCrossRef Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir. 2009;151:1349–58.PubMedCrossRef
6.
Zurück zum Zitat Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012.
7.
Zurück zum Zitat Louis DN, International Agency for Research on Cancer, World Health Organization, Deutsches Krebsforschungszentrum Heidelberg. WHO classification of tumours of the central nervous system. Lyon Geneva, Switzerland: International Agency for Research on Cancer, Distributed by WHO Press, World Health Organization; 2007. p. 309. Louis DN, International Agency for Research on Cancer, World Health Organization, Deutsches Krebsforschungszentrum Heidelberg. WHO classification of tumours of the central nervous system. Lyon Geneva, Switzerland: International Agency for Research on Cancer, Distributed by WHO Press, World Health Organization; 2007. p. 309.
8.
Zurück zum Zitat Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:499–508.PubMedCrossRef Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:499–508.PubMedCrossRef
Metadaten
Titel
Delayed response and survival from NovoTTF-100A in recurrent GBM
verfasst von
J. Lee Villano
Leena E. Williams
Karriem S. Watson
Nandini Ignatius
Marquess T. Wilson
Tibor Valyi-Nagy
Edward A. Michals
Herbert H. Engelhard
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0338-1

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.